RSV Vaccination Guidelines for High-Risk Adults

High-Risk Categories Based on Age

Adults aged ≥75 years should receive RSV vaccination due to significantly higher risk of severe outcomes, regardless of comorbidities 1, 2
Adults aged 60-74 years with specific risk factors should receive RSV vaccination 1, 3, 4
Some countries recommend vaccination for all adults ≥65 years or ≥60 years 1, 2, 5

High-Risk Medical Conditions

Chronic obstructive pulmonary disease (COPD) is a high-risk condition for RSV infection 1, 2
Asthma is a high-risk condition for RSV infection 1, 3
Bronchiectasis is a high-risk condition for RSV infection 1, 3
Interstitial lung disease is a high-risk condition for RSV infection 1, 3
Chronic respiratory failure is a high-risk condition for RSV infection 1, 3
Chronic heart failure is a high-risk condition for RSV infection 1, 2
Other chronic cardiovascular diseases are high-risk conditions for RSV infection 1, 2
Chronic kidney disease, especially end-stage renal disease, is a high-risk condition for RSV infection 1, 2, 6
Diabetes, particularly with complications, is a high-risk condition for RSV infection 1, 2, 7
Chronic liver disease is a high-risk condition for RSV infection 1, 2, 6
Chronic neurological or neuromuscular diseases are high-risk conditions for RSV infection 1, 2
Severe obesity is a high-risk condition for RSV infection 1, 2

Immunocompromised Status

Solid organ transplant recipients are at high risk for RSV infection 1, 3, 6
Hematopoietic stem cell transplant recipients are at high risk for RSV infection 1, 3, 6
Patients with solid tumors or hematological malignancies are at high risk for RSV infection 1, 3, 6
Patients on immunosuppressive medications are at high risk for RSV infection 1, 3, 6
HIV-positive individuals are at high risk for RSV infection 6, 8

Living Situation

Residents of nursing homes or long-term care facilities are at high risk for RSV infection 1, 2, 8
Institutionalized individuals are at high risk for RSV infection 1, 2

Clinical Considerations

Immunosenescence (age-related immune decline) is a recognized risk factor for severe RSV disease, with comorbidities further increasing susceptibility 8
The burden of RSV in older adults has been underrecognized; it accounts for 10.6% of hospitalizations for pneumonia and 11.4% for COPD exacerbations 6

Vaccination Approach

A single intramuscular dose is recommended, preferably administered before or early in the RSV season (September-November) 4
Vaccination can be co-administered with seasonal influenza vaccine at different injection sites 4
If vaccine supply is limited, prioritize adults ≥75 years, those with multiple comorbidities, and residents of long-term care facilities 2, 4
Previous RSV infection does not confer long-lasting immunity and does not contraindicate vaccination 4

RSV Vaccination Age Recommendations

Age-Based Recommendations

The Centers for Disease Control and Prevention recommends RSV vaccination for all adults aged ≥75 years and for adults aged 60-74 years who are at increased risk for severe RSV disease 9
Adults aged 60-74 years with risk factors for severe RSV disease should receive a single dose of RSV vaccine 9, 10
For adults aged 50-59 years with risk factors, RSVPreF3 (Arexvy) is the only approved vaccine 11

Risk Factors for Adults Aged 60-74 Years

Adults aged 60-74 years with chronic kidney disease, especially end-stage renal disease, should receive RSV vaccination 9
Adults aged 60-74 years with chronic liver disease should receive RSV vaccination 9
Adults aged 60-74 years with chronic neurological or neuromuscular conditions should receive RSV vaccination 9
Adults aged 60-74 years with severe obesity (BMI ≥40 kg/m²) should receive RSV vaccination 9
Adults aged 60-74 years with moderate or severe immunocompromise should receive RSV vaccination 9
Residence in a nursing home or long-term care facility is a risk factor for severe RSV disease, and vaccination is recommended 9, 12
Frailty or dementia is a risk factor for severe RSV disease, and vaccination is recommended 11

Administration Guidelines

Only a single lifetime dose of RSV vaccine is recommended for adults 9
Adults who have previously received any RSV vaccine should not receive another dose 9, 10
RSV vaccine can be co-administered with seasonal influenza vaccine at different injection sites 11
Vaccination is preferably administered between September and November, before or early in the RSV season 11

Clinical Considerations

Patient attestation is sufficient evidence of the presence of a risk factor; extensive medical documentation should not be required 9
If vaccine supply is limited, priority should be given to those of more advanced age, those with multiple comorbidities, and residents of long-term care facilities 12

RSV Vaccination Frequency in Adults

Current Dosing Recommendation

Adults should receive only a single lifetime dose of RSV vaccine and should not receive another dose if they have already been vaccinated, as recommended by the Advisory Committee on Immunization Practices (ACIP) 13, 14
A single dose of RSV vaccine provides protection for at least two consecutive RSV seasons, and no additional doses are currently recommended, according to the Advisory Committee on Immunization Practices (ACIP) 13, 14

Duration of Protection

Current evidence demonstrates that one dose provides protection lasting through at least two RSV seasons 13, 14
The need for additional RSV vaccine doses will be evaluated by the Advisory Committee on Immunization Practices (ACIP) in the future as more data on duration of protection and immune response after revaccination become available 13

Optimal Timing for the Single Dose

Eligible adults who have not previously received RSV vaccination may be vaccinated at any time of year, as stated by the Advisory Committee on Immunization Practices (ACIP) 13, 14
Vaccination will have the most benefit if administered in late summer or early fall (August-October in most of the continental United States), just before the RSV season, according to the Advisory Committee on Immunization Practices (ACIP) 13, 14

Important Clinical Caveat

The single-dose recommendation applies to all three FDA-approved RSV vaccines, and there is no annual or periodic revaccination schedule for RSV vaccine in adults, as recommended by the Advisory Committee on Immunization Practices (ACIP) 15, 16

RSV Vaccination Guidelines for Adults

Age-Based Vaccination Criteria

The American College of Pulmonology recommends that all adults aged ≥75 years should receive a single dose of RSV vaccine, due to significantly elevated rates of hospitalization, severe disease, and mortality in this age group 17, 18
Adults aged 60-74 years with chronic medical conditions, such as COPD, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, or nursing home residence, should also be vaccinated 17, 18
RSVPreF3 (Arexvy) is the only vaccine approved for adults aged 50-59 years with risk factors for severe RSV disease, including chronic respiratory conditions, cardiovascular disease, metabolic conditions, renal disease, hepatic disease, neurological conditions, immunocompromise, living situation, and frailty 17

Dosing and Administration Guidelines

The vaccine should preferably be administered between September and November, before or early in the RSV season, to maximize protection 17
RSV vaccine can be co-administered with seasonal influenza vaccine at different injection sites 17
Data on co-administration with other vaccines, such as pneumococcal, herpes zoster, and COVID-19, are currently lacking 17

Clinical Implementation Considerations

Previous RSV infection does not confer long-lasting immunity and does not contraindicate vaccination, as reinfections are common due to short-lived immune responses 18
If vaccine supply is limited, prioritize adults aged ≥75 years, followed by adults aged ≥50 years with multiple comorbidities, and then residents of long-term care facilities 17

RSV Vaccine Age Recommendations

Age-Based Vaccination Guidelines

The Centers for Disease Control and Prevention recommends that all adults aged ≥75 years should receive a single dose of RSV vaccine, and adults aged 60-74 years should receive it if they have any chronic medical conditions or risk factors for severe disease 19
Universal vaccination is recommended for all adults aged 75 years and older, regardless of health status or comorbidities, due to significantly elevated rates of RSV-associated hospitalization, severe disease, and mortality 19
Vaccination is recommended for adults aged 60-74 years with risk factors, including chronic respiratory conditions, cardiovascular disease, metabolic conditions, chronic kidney disease, chronic liver disease, neurologic or neuromuscular conditions, severe obesity, or moderate or severe immunocompromise 19

Dosing and Administration

The Advisory Committee on Immunization Practices recommends that only one dose of RSV vaccine is recommended for a lifetime, and adults who have already received any RSV vaccine should not receive another dose 19
A single dose provides protection for at least two consecutive RSV seasons, and the need for additional doses will be evaluated by ACIP in the future as more data become available 19
Vaccination should preferably occur in late summer or early fall, just before RSV season begins, but eligible adults who have not been vaccinated may receive the vaccine at any time of year 19

Important Clinical Considerations

Patient attestation alone is sufficient evidence of risk factors, and vaccination should not be denied due to lack of medical documentation, according to the Centers for Disease Control and Prevention 19
Adults aged ≥75 years should not be delayed vaccination while waiting for documentation of risk factors, as age alone is sufficient indication 19
Adults aged 60-74 years who attest to having risk factors should not be withheld vaccination, even without formal medical records 19

RSV Vaccination Efficacy and Duration

Vaccine Efficacy

RSVPreF3 (Arexvy) maintains efficacy for at least three seasons with cumulative efficacy of 62.9% against RSV-associated lower respiratory tract disease over three seasons 20, 21
RSVpreF (Abrysvo) demonstrates sustained protection for at least two seasons with cumulative efficacy of 58.8% with ≥2 symptoms and 81.5% with ≥3 symptoms over two seasons 21, 22

Duration of Protection

The single-dose recommendation is based on demonstrated sustained efficacy over multiple seasons, unlike influenza where annual vaccination is required due to antigenic drift 20, 21

RSV Immunization Guidelines

Available RSV Immunizations by Population

The American Thoracic Society recommends RSVPreF3 (Arexvy) for adults aged ≥50 years with risk factors and all adults aged ≥60 years 23, 24
The American Thoracic Society recommends RSVpreF (Abrysvo) for adults aged ≥60 years 23, 24
A third mRNA-based RSV vaccine (mRNA-1345) has been approved in Europe for adults aged ≥60 years, though it is not available in all countries 24

Who Should Receive RSV Vaccination

The Centers for Disease Control and Prevention recommends that all adults aged ≥75 years should receive a single dose of RSV vaccine regardless of comorbidities 23, 25
The Centers for Disease Control and Prevention recommends RSV vaccination for adults aged 60-74 years with risk factors, including chronic obstructive pulmonary disease (COPD), asthma, heart failure or coronary artery disease, diabetes mellitus, chronic kidney disease, chronic liver disease, immunocompromise, frailty or dementia, and residence in a nursing home or long-term care facility 23, 25, 26

Administration Guidelines

The American College of Physicians recommends a single lifetime dose of RSV vaccine, with no booster doses indicated at this time, and the vaccine should preferably be administered between September and November (or August-October in some regions) 23, 25
The American College of Physicians recommends that RSV vaccine can be co-administered with seasonal influenza vaccine at different injection sites 23

Vaccine Efficacy and Duration

RSVPreF3 demonstrates 82.6% efficacy against RSV-associated lower respiratory tract disease and 94.1% efficacy against severe disease in the first season 24
RSVpreF shows 88.9% efficacy against RSV-associated lower respiratory tract infection with ≥3 symptoms in the first season 24

Important Clinical Considerations

The Infectious Diseases Society of America recommends that patient attestation alone is sufficient evidence of risk factors, and vaccination should not be denied due to lack of formal medical documentation 23, 25
The Infectious Diseases Society of America recommends that previous RSV infection does not confer long-lasting immunity and does not contraindicate vaccination 25
The National Foundation for Infectious Diseases recommends that if vaccine supply is limited, prioritize in the following order: adults aged ≥75 years, adults aged ≥50 years with multiple comorbidities, and residents of long-term care facilities 23, 25, 26

RSV Vaccine Safety in the Elderly

Safety Profile Overview

The Centers for Disease Control and Prevention recommends that the benefits of RSV vaccination in preventing severe disease, hospitalization, and death be weighed against the potential increased risk of Guillain-Barré syndrome with protein subunit vaccines, such as Arexvy and Abrysvo, in elderly adults 27, 28

Critical Safety Signal: Guillain-Barré Syndrome

The American College of Physicians notes that postlicensure surveillance has identified a potential increased risk of Guillain-Barré syndrome following protein subunit RSV vaccination, specifically with GSK's Arexvy and Pfizer's Abrysvo, leading to important changes in vaccination recommendations 27, 28
The Advisory Committee on Immunization Practices concluded that for adults aged 60-74 years without risk factors, the benefits of vaccination did not clearly outweigh potential harms, leading to a risk-based rather than universal recommendation 27, 28

Safety in Special Populations

The National Institute on Aging recommends that all adults aged ≥75 years should receive RSV vaccination regardless of health status or frailty, as frailty and nursing home residence are recognized risk factors for severe RSV disease 28
The American Geriatrics Society notes that patients with multiple comorbidities, such as chronic cardiovascular disease, chronic lung disease, and diabetes, benefit substantially more from vaccination than they are at risk from vaccine-related adverse events 28

Risk-Benefit Analysis

The Centers for Disease Control and Prevention estimates that the number of RSV-associated hospitalizations, ICU admissions, and deaths preventable over two RSV seasons per 1 million vaccine doses administered exceeds the estimated number of potential vaccine-attributable Guillain-Barré syndrome cases, supporting vaccination in high-risk populations 27

RSV Infection in Elderly Patients: Clinical Considerations and Prevention

Cardiovascular Complications

Acute cardiac events occur in 22.4% of hospitalized RSV patients, with rates reaching 33% in those with pre-existing cardiovascular disease 29
Heart failure exacerbation during RSV hospitalization independently increases mid- to long-term mortality (adjusted HR 1.86) 29
Atrial fibrillation during hospitalization increases short-term mortality (adjusted HR 1.66) 29
Chronic kidney disease is a significant predictor of RSV hospitalization (OR 4.37) 29

Mortality and Outcomes

Patients aged ≥75 years have significantly worse outcomes, with 30-day mortality hazard ratio of 2.85 compared to younger adults 30

Prevention and Management

The American College of Cardiology and other guideline societies recommend close monitoring for cardiac complications in elderly RSV patients, particularly those with pre-existing cardiovascular disease 29

Adult Respiratory Syncytial Virus (RSV) Vaccination Recommendations (ACIP)

Eligibility Criteria

Adults ≥ 75 years should receive a single lifetime dose of RSV vaccine regardless of health status, because this age group experiences markedly higher rates of RSV‑related hospitalization, severe disease, and mortality. (Strong ACIP recommendation) 31, 32
Adults 60–74 years are recommended to be vaccinated only when at least one qualifying risk factor is present (e.g., chronic heart failure, COPD, diabetes with complications, moderate/severe immunocompromise, residence in long‑term care, frailty, etc.). This risk‑based approach reflects post‑licensure safety data indicating a possible Guillain‑Barré syndrome (GBS) signal with protein‑subunit vaccines. (Conditional ACIP recommendation) 31, 32
Adults 50–59 years may be vaccinated with RSVPreF3 (Arexvy) if they have qualifying risk factors; however, the ACIP has not issued a formal recommendation for this age group due to limited evidence on safety, durability of protection, and immunogenicity in immunocompromised persons. (No formal ACIP recommendation) 33

Qualifying Risk Factors (for ages 60–74)

Cardiovascular: chronic heart failure, coronary artery disease, congenital heart disease (isolated hypertension does not qualify).
Respiratory: chronic obstructive pulmonary disease, asthma, emphysema, interstitial lung disease, cystic fibrosis, bronchiectasis.
Metabolic/Renal: end‑stage renal disease or dialysis dependence, diabetes with complications (e.g., insulin requirement, end‑organ damage).
Neurologic/Neuromuscular: conditions impairing airway clearance or respiratory muscle strength, post‑stroke dysphagia, amyotrophic lateral sclerosis, muscular dystrophy.
Other Chronic Conditions: cirrhosis, sickle‑cell disease or thalassemia, severe obesity (BMI ≥ 40 kg/m²).
Immunocompromise: moderate/severe immunosuppression (per COVID‑19 guidance), solid organ or hematopoietic stem‑cell transplant, malignancy, immunosuppressive medications.
Living Situation/Functional Status: residence in nursing homes or long‑term care facilities (account for ~17 % of RSV hospitalizations), frailty (≥ 3 Fried criteria), dementia. (All derived from ACIP risk‑factor list) 32

Vaccine Options

Arexvy (GSK) – protein subunit vaccine.
Abrysvo (Pfizer) – protein subunit vaccine.
mResvia (Moderna) – mRNA vaccine.

Dosing Schedule & Duration of Protection

Single lifetime dose is recommended; individuals who have already received any RSV vaccine should not receive an additional dose. (Strong ACIP recommendation) 31, 34
One dose provides protection for at least two consecutive RSV seasons. (Evidence from clinical trials and post‑licensure data) 31, 34
The need for booster doses will be reassessed as further data on durability become available. (Future ACIP evaluation) 33, 34

Optimal Timing & Co‑Administration

Vaccinate in late summer or early fall (August–October in the continental U.S.) to align with the onset of RSV season and maximize benefit. (ACIP timing guidance) 31, 34
Vaccination may be performed at any time of year if needed, but the recommended window offers the greatest protection. (Flexibility noted by ACIP) 31, 34
Co‑administration with seasonal influenza vaccine is permissible when given at separate injection sites. Data on simultaneous administration with pneumococcal, herpes zoster, or COVID‑19 vaccines are currently lacking. (ACIP co‑administration guidance) 31, 34

Documentation & Provider Flexibility

Patient self‑attestation of a qualifying risk factor is sufficient; lack of formal medical documentation should not preclude vaccination. (ACIP implementation policy) 32
Qualified vaccinators (pharmacists, nurse practitioners, etc., per state law) may determine eligibility based on clinical assessment. (ACIP provider authority) 32
Clinicians may offer the vaccine to patients they judge to be at increased risk even if the patient does not fall within a listed category, supporting flexibility in remote or underserved settings. (ACIP provider discretion) 31

Safety Considerations

Potential increased risk of Guillain‑Barré syndrome (GBS) has been identified after receipt of protein‑subunit RSV vaccines (Arexvy, Abrysvo). A self‑controlled case series of Medicare beneficiaries showed a higher incidence of GBS during days 1–42 post‑vaccination compared with days 43–90. (Observational safety signal) 32
Patients receiving protein‑subunit vaccines should be informed of the possible GBS risk as part of shared decision‑making. (ACIP safety communication) 31
Modeling indicates that the number of preventable RSV‑related hospitalizations, ICU admissions, and deaths in high‑risk populations exceeds the estimated vaccine‑attributable GBS cases, supporting a favorable risk‑benefit profile for eligible adults. (Benefit‑risk analysis) 32
For adults ≥ 75 years and for adults 60–74 years with qualifying risk factors, the ACIP concludes that benefits substantially outweigh risks. (Strong ACIP endorsement) 32

Contraindications

Standard vaccine contraindications apply (e.g., severe allergic reaction to any vaccine component). (ACIP standard practice) 31
For protein‑subunit vaccines, the GBS risk discussion is required as part of the contraindication/precaution counseling. (ACIP precaution) 31, 34